Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.54 USD | -0.94% | -0.27% | -2.39% |
May. 24 | Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi | MT |
May. 24 | Novavax awaits FDA decision on whether its next COVID shot can be offered in US | RE |
Sales 2024 * | 46.3B 50.21B | Sales 2025 * | 49.84B 54.06B | Capitalization | 112B 121B |
---|---|---|---|---|---|
Net income 2024 * | 7.08B 7.68B | Net income 2025 * | 8.7B 9.44B | EV / Sales 2024 * | 2.56 x |
Net Debt 2024 * | 6.68B 7.25B | Net Debt 2025 * | 2.28B 2.47B | EV / Sales 2025 * | 2.29 x |
P/E ratio 2024 * |
16
x | P/E ratio 2025 * |
12.9
x | Employees | 86,088 |
Yield 2024 * |
4.32% | Yield 2025 * |
4.55% | Free-Float | 87.13% |
Latest transcript on Sanofi
1 day | -0.94% | ||
1 week | -0.27% | ||
Current month | -1.40% | ||
1 month | -1.66% | ||
3 months | -0.47% | ||
6 months | +2.88% | ||
Current year | -2.39% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 19-08-31 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 21-12-31 |
Chief Tech/Sci/R&D Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 14-04-30 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 20-05-21 |
Frédéric Oudéa
CHM | Chairman | 60 | 22-09-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.56% | 9 M€ | -4.31% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 48.54 | -0.94% | 1,423,816 |
24-05-23 | 49 | -2.70% | 2,781,532 |
24-05-22 | 50.36 | +2.88% | 2,119,999 |
24-05-21 | 48.95 | +1.09% | 725,653 |
24-05-20 | 48.42 | -0.51% | 1,273,831 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- SAN Stock
- SNY Stock